Shares of Chimerix (CMRX) touched a new high of $5.15 yesterday, with the company moving one step closer to its goal of accelerating access to the first medicine specific to patients diagnosed with recurrent H3 K27M-mutant diffuse glioma.
H3 K27M-mutant diffuse glioma is a highly aggressive and rare form of brain cancer, classified as WHO Grade 4. It primarily affects children and young adults, with over 2,000 new cases diagnosed annually in the United States. Surgical resection is challenging due to the tumor's location, and current treatment options are limited to radiotherapy, though the tumor almost always recurs. Despite the severity of this condition, there are no approved therapies specifically targeting H3 K27M mutations. The median overall survival for patients is approximately one year from diagnosis, with survival dropping to just 5.1 months from recurrence.
For comments and feedback: editorial@rttnews.com